Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Catalyst Pharm Inc (CPRX)
Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,579,975
  • Shares Outstanding, K 106,611
  • Annual Sales, $ 214,200 K
  • Annual Income, $ 83,080 K
  • 60-Month Beta 1.11
  • Price/Sales 7.38
  • Price/Cash Flow 18.29
  • Price/Book 4.53
Trade CPRX with:

Options Overview Details

View History
  • Implied Volatility 31.90% ( +2.47%)
  • Historical Volatility 47.95%
  • IV Percentile 2%
  • IV Rank 9.97%
  • IV High 78.65% on 01/23/23
  • IV Low 26.72% on 11/30/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 160
  • Volume Avg (30-Day) 340
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 7,773
  • Open Int (30-Day) 8,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.43
  • Number of Estimates 4
  • High Estimate 0.48
  • Low Estimate 0.39
  • Prior Year 0.22
  • Growth Rate Est. (year over year) +95.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.27 +22.13%
on 11/09/23
15.07 -0.56%
on 12/04/23
+1.82 (+13.87%)
since 11/03/23
3-Month
11.55 +29.74%
on 10/02/23
15.07 -0.56%
on 12/04/23
+1.06 (+7.65%)
since 09/01/23
52-Week
11.09 +35.12%
on 06/01/23
22.11 -32.23%
on 01/13/23
-2.29 (-13.23%)
since 12/02/22

Most Recent Stories

More News
3 Robinhood Stocks to Buy Right Now

The no-cost trading platform's customers have their clear favorites, and they're more mainstream names than you might expect them to be.

AMZN : 144.26 (-1.88%)
CPRX : 14.93 (+0.74%)
ADBE : 599.93 (-2.05%)
2 Robinhood Stocks With Market-Beating Potential

These diamonds in the rough won't stay down.

CPRX : 14.93 (+0.74%)
O : 54.96 (+0.66%)
September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects......

CPRX : 14.93 (+0.74%)
NVO : 100.56 (+0.16%)
NVS : 98.57 (+0.45%)
SNPHY : 9.5200 (-0.32%)
3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa...

CPRX : 14.93 (+0.74%)
KNSA : 16.70 (-0.65%)
OPK : 1.5550 (+1.63%)
PFE : 29.42 (+1.76%)
3 Value Pharma Stocks to Keep Watching

The pharma industry’s ability to remain resilient in times of economic uncertainty offers an appealing investment opportunity. Hence, fundamentally sound pharma stocks Catalyst Pharmaceuticals (CPRX),...

CPRX : 14.93 (+0.74%)
MOR : 6.83 (-2.57%)
VYGR : 7.55 (-0.79%)
Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics...

CPRX : 14.93 (+0.74%)
NVO : 100.56 (+0.16%)
NVS : 98.57 (+0.45%)
SNPHY : 9.5200 (-0.32%)
Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals...

CPRX : 14.93 (+0.74%)
TEVA : 9.97 (+2.68%)
Is Catalyst Pharmaceuticals (CPRX) a Quality Investment?

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) delivered a robust performance in the first quarter of 2023. However, it fell short of analysts’ estimates. Let’s dig into some of its financial...

ABBV : 144.97 (+1.09%)
ALPMY : 12.1550 (-1.02%)
CPRX : 14.93 (+0.74%)
NVO : 100.56 (+0.16%)
Is Catalyst Pharmaceuticals (CPRX) a Buy in the Near Future?

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future?...

ABBV : 144.97 (+1.09%)
CPRX : 14.93 (+0.74%)
NVO : 100.56 (+0.16%)
NVS : 98.57 (+0.45%)
AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy...

ABBV : 144.97 (+1.09%)
CPRX : 14.93 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 15.51
2nd Resistance Point 15.18
1st Resistance Point 15.00
Last Price 14.93
1st Support Level 14.49
2nd Support Level 14.16
3rd Support Level 13.98

See More

52-Week High 22.11
Fibonacci 61.8% 17.90
Fibonacci 50% 16.60
Fibonacci 38.2% 15.30
Last Price 14.93
52-Week Low 11.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar